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Background: The incidence of melanoma, one of the most aggressive of the skin cancers, has been increasing
worldwide in the last few decades. Data from Latin America and Brazil remain scarce. We aimed to describe the
demographic, clinical, and histopathological data; therapy characteristics; and survival rates of the Brazilian
melanoma patient population.
Results: We collected and analysed retrospective data from 15 years at a tertiary cancer centre. We describe patient
characteristics and treatment. We calculated survival, and identified the main prognostic factors through univariate
and multivariate analysis. We analysed a total of 1073 patients, with a mean age of 56.7 years. Men and women
experienced similar prevalence, and 91.2% of patients had white skin. The most prevalent subtype was superficial
spreading, and the most prevalent anatomic location was the trunk (32.2%), followed by the lower extremities
(28%). Of all cases, 567 (52.9%) were assigned to clinical stages I and II, while 382 (32.6%) were stages III and IV.
Surgery was the main treatment. Sentinel node biopsy was performed in 373 patients, with 23.8% positivity. Overall
actuarial 5-year survival was 67.6%. Multivariate analysis showed that gender, serum lactate dehydrogenase (LDH)
levels at diagnosis; anatomic location, TNM stage, and local recurrence were significant prognostic factors.
Conclusions: Overall survival was lower than worldwide rates. The main factors influencing survival were similar to
those in other populations. Local recurrence was independently associated with lower survival rates. The high
prevalence of advanced cases reinforces the importance of strategies to diagnose melanomas in the early stages.
There is a need for future multi-institutional prospective studies to attain a better understanding of possible
socioeconomic and other influences on survival among melanoma populations in Brazil and Latin America.
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Skin neoplasmsBackground
Melanoma is a neoplasm arising from melanocytes [1] in
the skin, mucosa, or uvea. Melanoma constitutes less than
5% of skin cancers but is responsible for around 95% of
skin cancer deaths, and its incidence has been rising
worldwide over recent decades [2]. In the United States,
approximately 70,000 cases are diagnosed every year, with
approximately 9000 deaths. In Brazil, it is estimated that* Correspondence: viniciusvazquez@gmail.com
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unless otherwise stated.6000 new cases occur each year, resulting in 1300 deaths
[3-5]. Risk factors for melanoma development include ex-
posure to ultraviolet (UV) rays, as well as individual
phenotypical characteristics, such as fair skin/hair pigmen-
tation, presence of multiple nevi, immunosuppression, and
family history [6].
Melanoma prognosis is based on clinical and histo-
pathological factors. For localized disease, the primary
tumour thickness (Breslow) is the most important prog-
nostic factor. Tumour ulceration, mitotic rate, gender,
age, and serum levels of lactate dehydrogenase (LDH)
are also related to prognosis [7-10]. For metastatic dis-
ease, the presence and characteristics of lymph nodesl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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survival. Lymph node tumour burden and the diagnosis of
micrometastases by sentinel node biopsy (SNB) have been
shown to be closely associated with prognosis. Although
SNB is not intended as therapy, its results often change
therapeutic plans. In standard practice, patients with posi-
tive SNBs, as well as patients with clinically diagnosed
stage III disease, undergo lymph node dissection [11-14].
The different characteristics of melanoma and their re-
lation to prognosis have been extensively reviewed
[7,8,10,15]. In 2001, melanoma became the first cancer
to be staged using an evidence-based system created on
an extensive multi-institutional database (more than
17,000 melanoma cases) by the American Joint Committee
on Cancer and the International Union Against Cancer
(UICC) [8]. Unfortunately, this database included no Latin
American or Brazilian patients. Skin phenotype and sun
exposure are factors associated with melanoma incidence,
while early diagnosis and easy access to healthcare are re-
lated to the prognosis. The Brazilian population is made
up of multiple races, with many people of more than one
racial heritage, and, hence, a range of skin colours. The
population is frequently exposed to UV radiation. Access
to healthcare is often difficult, especially for those living in
rural areas. The Latin America and/or Brazilian published
data are limited to descriptive studies or related to treat-
ment in small series, and none has investigated survival or
prognosis [16].
We sought to characterize Brazilian melanoma pa-
tients according to demographic, clinical, and histo-
logical data, as well as treatment, and to analyse the
main factors related to prognosis.
Results
The study included 1073 patients, whose demographic
characteristics are presented in Table 1. The main clin-
ical and histopathological features are shown in Table 2
and treatment characteristics in Table 3. Sao Paulo State
was the origin of 781 (72.8%) patients, followed by Minas
Gerais with 128 (11.9%). The more distant areas—the





Skin colour, n (%)
White 978 (91.2)
Other 87 (8.1)
Not available 8 (0.7)
Age, range (mean, SD) 1-95 (56.7, 16.0)cases (15%). From Sao Paulo State, 160 patients were from
the Barretos area (20.5%) and 621 (79.5%) from other
areas. The anatomical and histological subtype distribu-
tions of primary tumours differed according to skin colour
characteristics. Compared with patients with white skin, a
higher proportion of those with non-white skin presented
with melanomas in the lower extremities (27.9 versus
54.1% p < 0.001) and more of the acral subtype (5.6 versus
18.5% p = 0.002). Of 34 non-white patients with tumours
in the lower extremities, 10 presented with acral lentigi-
nous melanomas (29.4%), 11 with nodular (32.4%), seven
with superficial spreading (20.6%), one with lentigo
maligna (2.9%), and five other/not otherwise specified
(14.7). Women presented with more melanomas in the
lower extremities than men (36.3 versus 23.2%; p < 0.001),
and fewer in the trunk (29 versus 40%; p < 0.001). The
superficial spreading histologic subtype was generally
more prevalent among women (43.6 versus 33.7%; p =
0.035), while the nodular subtype was more common
among men (34.6 versus 28.5%; p = 0.035).
In accordance with international treatment guidelines,
surgery was the most common treatment modality, with
a few patients receiving adjuvant radiation or systemic
therapy. Amputation was mainly used to treat tumours
in fingers/toes and advanced tumours of the extremities;
no amputations were necessary to treat complications.
Of the 135 patients not operated on for the primary
tumour, 95 had received previous treatment at other in-
stitutions and 60 cases were stage IV; 33 were stage III
or featured nodal recurrence. Twenty-nine patients
underwent surgery at our institution. Twenty-seven pa-
tients received no treatment. These were advanced cases
and/or refused treatment. In 373 cases, sentinel node bi-
opsy (SNB) was performed using preoperative dynamic
lymphoscintigraphy with 99mTc-labelled sulphur colloid
and intraoperative blue dye and a gamma probe [17].
The rate of positivity was 23.8% (89 patients). Thirty-
three cases (8.8%) had technical problems, or data were
unavailable from the referring site. Among the 74 posi-
tive sentinel node cases with known tumour thickness
(pT), only four cases (6.3%) were ≤ 1 mm (pT1), 16
(17.2%) were pT2, 18 (23.4%) were pT3, and 36 (41.9%)
were pT4 (Table 4). Of the 284 negative cases (76.2%),
locoregional recurrence occurred in 28 (9.8%).
Survival analysis included 915 patients. At the last
evaluation, 513 (56.1%) were alive and disease-free, 46
(5.0%) were alive with cancer, 266 (29.1%) had died due
to melanoma, 79 (8.6%) had died from other causes, six
(0.7%) died due to unknown causes, and five (0.5%) were
lost to follow-up. Follow-up duration ranged from 6 to
233 months (mean 52 [SD 45] median, 38 months). For all
patients alive at the last evaluation (559 cases), the mean
follow-up was 63.5 months (SD 45), median 62 months. In
61.2% follow-up lasted longer than 3 years. Only five
Table 2 Main clinical and histological characteristics of
1073 melanoma patients
Characteristics Number %
Anatomical location (primary tumour)
Trunk 347 32.2
Lower extremities 300 28.0
Head and neck 197 18.4




Not available 66 6.2
Histological subtype
Superficial spreading 353 32.9
Nodular 288 26.8
Acral lentiginous 76 7.1
Lentigo maligna melanoma 40 3.7
Other/not classified 156 14.6
Not available 160 14.9
Tumour depth (Breslow)
Up to 1.0 mm 225 21.0
1.1 to 2.0 mm 184 17.1
2.1 to 4.0 mm 171 15.9
More than 4.0 mm 231 21.5










Not available 395 36.8
Mitotic index
Up to 1 mitosis/mm2 104 9.7
More than 1 mitosis/mm2 260 24.2






Not available 212 19.8
Table 2 Main clinical and histological characteristics of






Not available 124 11.6
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the 5-year disease-specific survival (DSS) rate was 67.6%
(Figure 1).
Univariate analysis showed that the following demo-
graphic, clinical, and histological variables were related
to prognosis: age (p = 0.005; Hazard Ratio = 1.011), gen-




Not operated 135 12.6
Primary closure 385 35.8
Local surgery* 257 20
Local surgery and reconstruction (graft or flap) 213 23.8
Amputation 64 6.0



















Not available 422 39.3
*Reconstructive surgery information not available.
Table 4 Tumour thickness in patients submitted to
sentinel node biopsy
Tumour thickness (pT) Total Positive Negative
pT1, n (%) 63 (16.9) 4 (6.4) 59 (93.6)
pT2, n (%) 93 (24.9) 16 (17.2) 77 (82.8)
pT3, n (%) 77 (20.6) 18 (23.4) 59 (76.6)
pT4, n (%) 86 (23.0) 36 (41.9) 50 (58.1)
Not available, n (%) 54 (14.5) 15 (27.8) 39 (72.2)
Thickness in mm, mean (SD) 3.3 (3.2) 5.0 (4.4) 2.7 (2.4)
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ceration, and microscopic satellitosis. Vascular and/or
lymphatic infiltration were not statistically significant
predictors of survival (Tables 5 and 6).
According to clinical stage and recurrence status, all
TNM variables, presence of locoregional or distant re-
currence, and serum LDH levels were associated with
prognosis (Table 7). Women had higher survival rates
than men (Table 5). TNM stage distribution also differed
according to sex, with a higher percentage of women
with lower stage disease than men (Table 8).
Multivariate analysis demonstrated that gender, TNM
stage, LDH levels at diagnosis, the anatomic location of
the primary tumour, and locoregional recurrence were
associated with prognosis (Table 9) (Figure 2).
Discussion
For many years, numerous studies have investigated
characteristics of melanoma patients and prognostic fac-
tors. However, data from Latin America and Brazil re-
main scarce. The current demographic distribution ofFigure 1 Cancer-specific survival for all melanoma patients.melanoma in the Brazilian population is similar to
worldwide data [18], with an equal gender distribution,
and a mean age of diagnosis at around the sixth decade
of life. The majority of patients had white skin (91.4%).
However, people in Brazil with moderately brown skin
colour typically declare themselves as ‘white’, and our study
did not discriminate the skin phototype [19]. Supporting
the accurate self-reporting of skin colour, the acral subtype
was low among the white-skinned patients (5.5%), which
would likely not have been the case with mixed phototypes.
The accuracy of self-reporting is also supported by the ap-
proximately one-third of non-white-skinned patients pre-
senting with acral lentiginous melanomas.
This study included seven patients under 18 years old;
two of whom died from melanoma. Although these pa-
tients may have had different predisposing conditions,
they were kept in the cohort and in the survival analysis
to illustrate the spectrum of the disease.
In terms of patient origin, two-thirds of patients came
from Sao Paulo State and of these, only 21% lived in the
region of our cancer centre. Considering that Sao Paulo
State has 645 cities with total area of 248,222 km2, the ma-
jority of patients came far from their homes for treatment.
As previously found in Caucasian populations, we ob-
served a prevalence of the superficial spreading histologic
subtype, followed by nodular melanoma. The anatomic
distribution of lesions showed that the trunk was a more
prevalent site in men, and the lower extremities were
more prevalent in women, similar to the findings of other
epidemiologic studies [18].
Univariate and multivariate analyses showed higher
survival rates for women. Interestingly, women more
Table 6 Disease-specific survival (DSS) according to
clinical and histological characteristics
Variable Category n 5-year
SCS (%) p
Anatomical location Upper limbs 139 75.9
<0.001
Trunk 303 72.0
Head and neck 172 65.3
Lower limbs 264 62.1
Unknown 7 50.0
Sentinel node Negative 258 80.6
<0.001
Positive 77 54.9





Histological subtype Acral lentiginous 53 50.5
<0.001
Nodular 258 61.3
Superficial Spreading 326 82.3
Lentigo maligna 34 87.5
Not classified/other 136 86.4


















Perineural invasion Yes 14 68.8
0.974
No 303 67.9
Ulceration Present 260 56.8
<0.001
Absent 332 78.0
Regression Yes 57 73.3
0.863
No 413 69.2
Microscopic satellitosis Yes 44 37.2
<0.001
No 403 74.0
Table 5 Disease-specific survival (DSS) according to
demographic categories
Variable Categories n 5-year DSS (%) p
Gender Male 448 59.1 <0.001
Female 467 75.6
Skin colour White 840 67.8 0.784
Other 68 69.3
Table 7 Disease-specific survival (DSS) according to
clinical stage and recurrence status
Variable Category n 5-year
DSS (%)
p








M M0 732 72.4 < 0.001
M1 105 26.1




Distant recurrence Absent 653 87.9 < 0.001
Visceral 177 18.4
Non-visceral 53 35.9
Locoregional recurrence Yes 122 33.5 < 0.001
No 753 74.8
Serum lactate dehydrogenase ≤480 IU/L 614 74.0 <0.001
>480 IU/L 102 55.4
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was a factor strongly related to higher survival rates.
The used treatment modalities were in accordance with
international trends. For localized melanoma, most pa-
tients underwent only surgery. The 135 (12.6%) of patients
not operated on for the primary tumour are explained
mainly by the 14.3% of patients presenting in clinical stage
IV and patients presenting with recurrences having had
previous treatment at other institutions. Sentinel node bi-
opsy (SNB) was indicated in one-third of patients.
The overall rate of SNB was relatively low, as this pro-
cedure was only routinely performed starting in 2003.
The number of pT3 and pT4 cases undergoing SNB andTable 8 Gender distribution according to TNM stage
Stage (TNM) Male n (%) Female n (%)
0 (In Situ) 40 (7.6) 58 (11.1)
I 122 (23.3) 175 (33.3)
II 131 (25.0) 140 (26.7)
III 122 (23.3) 92 (17.6)
IV 109 (20.8) 59 (11.3)
p < 0.001.
Table 9 Multivariate analysis of melanoma-specific survival
Variable Category n HR 95% CI (HR) p value
Gender Male 188 1.000 - -
Female 221 0.508 0.314; 0.822 0.006
Age - 409 1.005 0.988; 1.021 0.582
DHL - 409 1.003 1.001; 1.004 <0.001
Anatomical location Head and neck 75 1.000 - -
Lower limbs 126 0.575 0.305; 1.084 0.087
Upper limbs 61 0.398 0.181; 0.878 0.022
Trunk 147 0.429 0.226; 0.814 0.010
Histological subtype Acral lentiginous 30 1.000 - -
Nodular 149 0.777 0.368; 1.642 0.509
Superficial spreading 190 0.889 0.399; 1.981 0.774
Lentigo maligna 14 0.516 0.098; 2.702 0.433
Not classified/other 26 0.305 0.077; 1.207 0.091
Ulceration Present 167 1.000 - -
Absent 242 0.902 0.554; 1.468 0.678
T T1 105 1.000 - -
T2 104 3.005 1.135; 7.957 0.027
T3 84 2.502 0.862; 7.264 0.092
T4 116 4.264 1.479; 12.293 0.007
N N0 310 1.000 - -
N1 34 2.143 1.058; 4.340 0.034
N2 31 2.163 1.072; 4.367 0.031
N3 34 3.249 1.772; 5.954 < 0.001
M M0 395 1.000 - -
M1 14 3.658 1.633; 8.192 0.002
Locoregional recurrence No 367 1.000 - -
Yes 42 2.198 1.307; 3.696 0.003
Vazquez et al. BMC Research Notes  (2015) 8:4 Page 6 of 9the mean thickness (3.2 mm) explains the high (23.4%)
positivity rate. pT1 and pT2 positivity was 6.3 and
17.2%, respectively, contrasting with the 23.4% of T3 and
41.9% of T4 tumours, showing the correlation of positivity
with thickness. In the literature, the positivity rate varies
from 12 to 26% [20-23]. The 9.8% rate of locoregional re-
currence among cases with negative SNB is high. How-
ever, this rate includes not only nodal lesions but also
local recurrence and in-transit metastases. There were a
significant number of patients (262, 24.4%), with no Bre-
slow information. Of these, 145 (54%) had stage III and IV
disease. SNB was performed in this situation in 54 cases
(14.5%). Unfortunately, our centre receives many patients
with previous excisional biopsy and no Breslow thickness
or other histopathological information. We tried to reana-
lyse the slides and paraffin blocks, but this was not pos-
sible for some cases. In such situations we lowered the
threshold for performing SNB for localized disease (clin-
ical stage I and II).Locoregional recurrence is not usually emphasized,
but was strongly related to prognosis, with significantly
lower survival rates, which indirectly shows the import-
ance of correct surgical treatment.
Systemic therapy at our institution was chemotherapy
and interferon alpha, which was indicated for systemic
disease (Stage IV or recurrence) or inoperable Stage III.
Surgery for metastatic disease was indicated frequently,
mainly for non-visceral disease. First-line chemotherapy
was dacarbazine. Second-line was carboplatin and pacli-
taxel or immunotherapy with interferon alpha. Target
therapy or modern immunotherapies are currently in use
at the institution, but were not applied to this population.
Radiation therapy was indicated mostly to palliate me-
tastases, and in selected cases, as an adjuvant setting
after lymphadenectomy. Indications were bulky tumours
(general) and head and neck lymph node metastasis.
This course of treatment is not well established but
there is evidence for its use in selected cases [24].
Figure 2 Melanoma-specific survival according to clinical stage.
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tients was low, but when stratified by clinical stage, it
was very similar to other larger series, including the
AJCC. These findings show that the higher number of
advanced stage cases impacted the overall survival. This
is somewhat expected in data from tertiary cancer cen-
tres, but is the opposite of findings from developed
countries with successful secondary skin cancer preven-
tion policies—related to early diagnosis—which have
achieved an overall survival of over 90% [10,25,26].
The presence of intratumoural lymphocyte infiltration,
a known factor related to prognosis, did not affect sur-
vival rates in this study. Vascular and/or lymphatic infil-
tration were related to a lower survival rate, but not to a
statistically significant degree. Other factors, including
mitotic index, sentinel node status, and microscopic
satellitosis, associated with prognosis in the univariate
analysis, could not be tested in the multivariate model,
because a relatively small number of patients remained
in the model. The lack of information from referring
sites impaired more inclusive analysis. A large number
of patients had also had their tumours excised in other
centres with little or no histological information on the
primary tumour. However, most cases were suitable for
univariate analysis and at least 400 cases were pooled in
the multivariate analysis.
The overall survival for the entire cohort was lower
than that observed in Caucasian melanoma populations.
As expected, our data confirmed that the major factors
related to melanoma prognosis are TNM stage, LDH
levels, and locoregional recurrence. Patients with head
and neck tumours had lower survival rates than patients
with trunk and upper extremity disease. Anatomiclocation, besides not being completely accepted as a prog-
nostic factor, has been associated with prognosis in other
studies, and was independently related to survival rate in
our cohort [15]. Other well-known prognostic factors,
such as ulceration and mitotic index, were found to be as-
sociated with survival only in the univariate analysis. This
may be related to the relatively small number of patients
in the present study, compared with the more than 17,000
cases that validate the UICC/AJCC staging system [8].
Other factors related to prognosis only in the univariate
analysis that were not confirmed as prognosticators in-
cluded age, acral lentiginous subtype, Clark level, and
microscopic satellitosis.
Conclusions
This study shows that Brazilian melanoma patients expe-
rienced a lower survival rate than the current worldwide
average. Our findings confirm the strong association be-
tween TNM stage and local recurrence to prognosis.
The high prevalence of advanced cases reinforces the
importance of local strategies to diagnose melanomas in
the early stages, and to treat it definitively. This retro-
spective study from a single institution has several limi-
tations, such as incomplete data and selection bias and it
remains important to perform multi-institutional pro-
spective studies to attain a better understanding of pos-
sible socioeconomic and racial disparities in Brazil and
Latin America that may affect access to treatment.
Methods
The study population included all patients diagnosed
with melanoma between January 1997 and December
2011 at the Barretos Cancer Hospital (BCH) in Barretos,
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tion focused on public health and is a high-volume tertiary
cancer centre, treating patients from all over the country
free of charge [27]. All data were collected from medical
records following the appropriate ethical guidelines, and
the local ethics committee approved the study (Barretos
Cancer Hospital Ethics Committee, #548/2011).
Data analyses were performed with software (SPSS for
Windows®, SPSS Inc., Chicago IL, USA). Patients who
were previously treated at other institutions were in-
cluded as long as their records included sufficient infor-
mation and at least 6 months of follow-up at the BCH.
Patients seen for second opinions with incomplete treat-
ment were excluded, as well as all in situ lesions. For
survival analysis, at least 24 weeks of follow-up were re-
quired. The variables were categorized as demographics
(gender, patient origin, age, and skin colour), clinical/
histological data (anatomic location of primary tumour;
level of serum LDH at first consultation; histological
subtype; Breslow depth; Clark level; presence of ulcer-
ation; mitotic index; perineural, vascular, and lymphatic
infiltration; and peri- and intratumoural lymphocyte in-
filtration), and treatment-related factors (surgery of pri-
mary tumour, sentinel node biopsy, systemic therapy,
and radiation therapy).
Indications for sentinel node biopsy were tumour
thickness ≥ 0.75 mm. Indications for SNB in tumours be-
tween 0.75 mm and 1.00 mm thickness were the pres-
ence of mitosis or ulceration. Stage IV and clinically
diagnosed stage III were contraindications to SNB.
Skin colour was recorded by the clinician. When this in-
formation was missing, it was collected from patient iden-
tification, which is registered based on self-report. Clinical
stage was determined using the 2009 UICC TNM system
[10]. Stages were not stratified into subdivisions for ana-
lysis. DSS analyses were performed according to the
Kaplan–Meier method, using the log-rank test to compare
survival curves. For the continuous variable age, we used
the Cox proportional hazards regression method; the vari-
ables associated with prognosis (p < 0.05 in univariate ana-
lysis) were included in the Cox regression multivariate
model analysis if at least 400 cases were available for test-
ing, with the calculation of the hazard ratio (HR) for death
and modelling according to variables of interest. Age,
TNM stage, and ulceration were used as adjusted model
variables, regardless of statistical significance [28]. Statis-
tical significance was set as 5% for all tests.
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